Table 3.
Determination of B-lymphocyte proliferation by cytometry-based cell counting
| Group | PI (without polymyxin B) | PI (with polymyxin B) |
|---|---|---|
| Control | 1.08±0.005 | 1.08±0.005 |
| LPS | 1.59±0.026&& | 1.19±0.02**,$$ |
| EBNL | 1.12±0.011&& | 1.16±0.012**,$$ |
| EBNM | 1.15±0.01&& | 1.19±0.012**,$$ |
| EBNH | 1.14±0.005&& | 1.24±0.02**,$$ |
Notes: A total of 10 μg polymyxin B/mL and 10 μg LPS/mL or EBNE (0.19 mg/mL, 0.38 mg/mL, or 0.75 mg/mL) were dissolved in media and incubated with cells for 72 hours at 37°C with 5% CO2. Following incubation, the B lymphocytes were stained with anti-CD19 for 30 minutes at 37°C in darkness. The samples were analyzed by flow cytometry. The data are the mean ± SD (n=3/treatment).
or
Significant difference from control group (P<0.01).
The PI (with polymyxin B) significant difference from the PI (without polymyxin B) (P<0.01).
Abbreviations: LPS, lipopolysaccharide; EBNL, EBN low dose; EBNM, EBN medium dose; EBNH, EBN high dose; EBNE, EBN extract; PI, proliferation index; SD, standard deviation; EBN, Edible bird’s nest.